Everyone asked me for this

Analyst Targets

• Consensus: Strong Buy — 17 Buy, 4 Hold, 0 Sell (TipRanks)
• Average 12-month price target: $481–$487 range across major desks
• Current price: ~$379 (Oct. 9 close), roughly 22% below the consensus target

What This Report Actually Is

Tuesday’s Q3 release is not a standard quarterly checkup. It is the first full earnings report since UnitedHealth raised its full-year adjusted guidance to $19.50–$20.00 per share in July and the first filed since CMS published the 2027 Medicare Advantage star ratings on October 8. Both of those facts matter for what investors will be listening for at 8:00 a.m. ET.

UnitedHealth is set to report Q3 2026 results on October 13, before the opening bell, with the Zacks consensus pegged at $4.12 per share on revenues of $111.38 billion. The company has beaten the consensus estimate in each of the last four quarters, with an average surprise of 12.1%. That track record is priced in; it is the guidance range that is not.

The Numbers to Watch

• EPS consensus: $4.12 (adjusted)
• Revenue consensus: ~$111.4 billion
• Full-year adjusted guidance: $19.50–$20.00 per share
• Medical care ratio (MCR) consensus: ~90.1%
• Q2 2026 MCR (baseline): 86.7%
• Q2 2026 adjusted EPS: $6.38, which beat the $4.94 consensus by $1.44

The Q2 medical cost ratio of 86.7% reflected cost and pricing discipline, as well as mix changes across all benefit offerings. MCR was aided by $860 million of net favorable prior period development, with the majority related to 2026 dates of service. Whether that reserve tailwind repeats in Q3 — or reverses — is the single most scrutinized line in Tuesday’s release.

Why the Stock Is Where It Is

UnitedHealth shares have fallen around 18% since July. Earnings on October 13 could spark a turnaround — or intensify selling pressure. The stock closed around $379 on Thursday and is sitting just above its 200-day moving average. A break below $356 would bring April’s unfilled gap into focus, while a sustained move above $408 would materially improve the chart outlook.

The compression from the July high reflects two concurrent anxieties: membership in Medicare Advantage plans is declining, with an expected loss of about 1.1 million members in 2026 as UnitedHealth and peers reduce offerings due to rising care costs, and the market is skeptical that the Q2 reserve benefit was repeatable.

The Star Ratings Wrinkle

The CMS release on October 8 rewrote the competitive landscape for 2028 bonus payments in a single afternoon. Humana said 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher in 2027, compared with just 20% in 2026. The improved ratings could meaningfully increase Humana’s 2028 quality bonus payment opportunity.

UnitedHealth moved in the opposite direction. J.P. Morgan estimates that UnitedHealth’s share of enrollments in plans rated four stars or higher will fall to about 67% from 81%, and CVS Health’s to roughly 70% from 84%. Three UnitedHealthcare plans received 5 stars for 2027. That is not a crisis, but it compresses the 2028 bonus pool at a moment when every dollar of margin counts.

Optum: The Other Pillar

As of the July update, UnitedHealth raised its full-year Optum operating earnings outlook to more than $13.45 billion, with UnitedHealthcare operating earnings targeted above $12.0 billion. The consensus marks for both UnitedHealthcare and total Optum operating income signal roughly 26–27% year-over-year increases. Optum’s margin trajectory — from roughly 2% in 2026 toward 4% in 2027 — is the medium-term story; any commentary Tuesday that either confirms or challenges that path will move the stock.

Bull / Base / Bear

Bull: MCR comes in below 89%, Optum margins confirm the recovery trajectory, and management reaffirms the $19.50–$20.00 floor. The stock gaps toward $408 resistance and analysts begin revising 2027 estimates higher.

Base: Numbers land near consensus, MCR is benign but the Q2 reserve tailwind does not repeat, and management holds guidance without raising it. The stock stabilizes in the $370–$390 range ahead of open enrollment data.

Bear: MCR prints above 90.5%, Optum margin guidance is trimmed, and the star ratings headwind prompts a cautious 2027 MA commentary. Below $356, risk shifts toward a retreat into April’s unfilled price gap.

Bottom Line

The debate around UNH has never really been about one quarter’s EPS. Medicare Advantage margins are tracking toward the upper half of the 2%–4% range, and management indicated the favorable trends seen in Q2 had held through late summer. Tuesday confirms or denies that. Combined with the star ratings shift that just handed Humana a structural advantage in 2028 bonus math, the report is less about $4.12 and more about whether the $19.50–$20.00 floor holds and what the company says about the road from there.